183 related articles for article (PubMed ID: 36530970)
1. PD-L1 is associated with the prognosis of penile cancer: A systematic review and meta-analysis.
Lu Y; Wang Y; Su H; Li H
Front Oncol; 2022; 12():1013806. PubMed ID: 36530970
[TBL] [Abstract][Full Text] [Related]
2. The Prevalence and Prognostic Role of PD-L1 in Upper Tract Urothelial Carcinoma Patients Underwent Radical Nephroureterectomy: A Systematic Review and Meta-Analysis.
Lu Y; Kang J; Luo Z; Song Y; Tian J; Li Z; Wang X; Liu L; Yang Y; Liu X
Front Oncol; 2020; 10():1400. PubMed ID: 32974145
[No Abstract] [Full Text] [Related]
3. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of different PD-L1 expression patterns and tumor-infiltrating lymphocytes in high-grade serous ovarian cancer: a systematic review and meta-analysis.
Wang YM; Cai W; Xue QM; Zhang JY; Zhou L; Xiong SY; Deng H
Front Immunol; 2023; 14():1234894. PubMed ID: 37654479
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis.
Qin Y; Luan J; Zhou X; Li Y
Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33704390
[TBL] [Abstract][Full Text] [Related]
6. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Zhang C; Yang Q
Front Oncol; 2020; 10():572203. PubMed ID: 33634012
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis.
Zhu L; Sun J; Wang L; Li Z; Wang L; Li Z
Front Pharmacol; 2019; 10():962. PubMed ID: 31616289
[No Abstract] [Full Text] [Related]
8. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
9. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.
He J; Chen XF; Xu MG; Zhao J
Arch Oral Biol; 2020 Jun; 114():104717. PubMed ID: 32344357
[TBL] [Abstract][Full Text] [Related]
10. The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Li Y; He M; Zhou Y; Yang C; Wei S; Bian X; Christopher O; Xie L
Front Pharmacol; 2019; 10():139. PubMed ID: 30873025
[No Abstract] [Full Text] [Related]
11. The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis.
Huang ZL; Liu S; Wang GN; Zheng SH; Ding SR; Tao YL; Chen C; Liu SR; Yang X; Chang H; Wang XH; Xia YF
Cancer Cell Int; 2019; 19():141. PubMed ID: 31139018
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis.
Zeng S; Liu D; Yu Y; Zou L; Jin X; Liu B; Liu L
Front Pharmacol; 2023; 14():1111061. PubMed ID: 36992842
[No Abstract] [Full Text] [Related]
13. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
Liu S; Gao W; Ning Y; Zou X; Zhang W; Zeng L; Liu J
Front Immunol; 2022; 13():908173. PubMed ID: 35880172
[TBL] [Abstract][Full Text] [Related]
14. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis.
Li S; Chen L; Jiang J
Medicine (Baltimore); 2019 Apr; 98(16):e15201. PubMed ID: 31008945
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of programmed cell death ligand-1 expression in patients with bladder urothelial carcinoma undergoing radical cystectomy: A meta-analysis.
Zhang J; Song L; Zhu H; Liu Q; Wang D
Front Immunol; 2022; 13():986911. PubMed ID: 36248912
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures.
Shi T; Zhu S; Guo H; Li X; Zhao S; Wang Y; Lei X; Huang D; Peng L; Li Z; Xu S
Front Oncol; 2021; 11():567978. PubMed ID: 33708622
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis.
Yang L; Xue R; Pan C
Onco Targets Ther; 2019; 12():3671-3682. PubMed ID: 31190869
[No Abstract] [Full Text] [Related]
18. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
19. The negative effect of antibiotics on RCC patients with immunotherapy: A systematic review and meta-analysis.
Luo Z; Hao S; Li Y; Cheng L; Zhou X; Gunes EG; Liu S; Chen J
Front Immunol; 2022; 13():1065004. PubMed ID: 36505435
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials.
Li X; Yan S; Yang J; Wang Y; Lv C; Li S; Zhao J; Yang Y; Zhuo M; Wu N
Front Oncol; 2020; 10():574752. PubMed ID: 33585195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]